IceCure Medical Announces Study Published In The British Journal Of Radiology Demonstrates IceCure's ProSense Is A Safe Procedure With 97.7% Technical Success Rate In Treating Tumors Of The Lung, Bone, And Soft Tissues
Portfolio Pulse from Benzinga Newsdesk
IceCure Medical's ProSense cryoablation technology has been highlighted in a study published in The British Journal of Radiology, demonstrating a 97.7% technical success rate in treating tumors of the lung, bone, and soft tissues. The study, conducted at the European Institute of Oncology, found ProSense to be safer, more cost-effective, and easier to manage compared to argon-based systems.
September 16, 2024 | 12:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
IceCure Medical's ProSense technology has been validated by a study showing high success rates and safety in treating tumors, which could boost investor confidence and potentially increase stock prices.
The study's publication in a reputable journal highlights the effectiveness and safety of IceCure's ProSense technology, which is likely to positively influence investor sentiment and drive up the stock price. The high success rate and cost-effectiveness compared to competitors strengthen IceCure's market position.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100